Ureter carcinoma
diseaseOn this page
Also known as carcinoma of the uretercarcinoma of ureterureter cancerureteral carcinoma
Summary
Ureter carcinoma (MONDO:0006481) is a cancer (an umbrella term covering 6 Mondo subtypes) and 49 clinical trials. Top therapeutic interventions include cisplatin, cabozantinib, and afatinib. A subtype of carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 49
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ureter carcinoma |
| Mondo ID | MONDO:0006481 |
| EFO | EFO:1000609 |
| DOID | DOID:4939 |
| NCIT | C8993 |
| SNOMED CT | 448864006 |
| UMLS | C0600079 |
| MedGen | 109002 |
| Anatomy (UBERON) | UBERON:0000056 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma of the ureter · carcinoma of ureter · ureter cancer · ureter carcinoma · ureteral carcinoma
Data availability: 1 cell line.
Disease family
This is a subtype of carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › ureter carcinoma
Related subtypes (48): retroperitoneum carcinoma, head and neck carcinoma, peritoneal carcinoma, neuroendocrine carcinoma, laryngeal carcinoma, bone carcinoma, carcinoma ex pleomorphic adenoma, scrotal carcinoma, skin carcinoma, malignant myoepithelioma, trachea carcinoma, epithelial-myoepithelial carcinoma, lipid-rich carcinoma, comedocarcinoma, in situ carcinoma, adenocarcinoma, urinary bladder carcinoma, breast carcinoma, squamous cell carcinoma, lung carcinoma, prostate carcinoma, renal carcinoma, uterine carcinoma, vulvar carcinoma, large cell carcinoma, undifferentiated carcinoma, basaloid carcinoma, cribriform carcinoma, digestive system carcinoma, fallopian tube carcinoma, penile carcinoma, sarcomatoid carcinoma, thymic carcinoma, transitional cell carcinoma, papillary carcinoma, Krebs 2 carcinoma, thyroid gland carcinoma, vaginal carcinoma, choroid plexus carcinoma, malignant epithelial tumor of ovary, mucin-producing carcinoma, basal cell carcinoma, carcinoma of urethra, combined carcinoid and adenocarcinoma, secondary carcinoma, invasive carcinoma, glycogen-rich carcinoma, lymph node carcinoma
Subtypes (6): regional ureteric cancer, ureter adenocarcinoma, ureter squamous cell carcinoma, ureter transitional cell carcinoma, ureter small cell carcinoma, carcinoma in situ of ureter
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 49.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 21 |
| Not specified | 14 |
| PHASE3 | 6 |
| PHASE1 | 6 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03244384 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer |
| NCT05092958 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study |
| NCT06349668 | PHASE3 | RECRUITING | Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery |
| NCT00942331 | PHASE3 | COMPLETED | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
| NCT03193788 | PHASE3 | UNKNOWN | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy |
| NCT03296306 | PHASE3 | UNKNOWN | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma |
| NCT03237780 | PHASE2 | ACTIVE_NOT_RECRUITING | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
| NCT04848519 | PHASE2 | ACTIVE_NOT_RECRUITING | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma |
| NCT04940299 | PHASE2 | ACTIVE_NOT_RECRUITING | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT04953104 | PHASE2 | ACTIVE_NOT_RECRUITING | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT00009867 | PHASE2 | COMPLETED | Arsenic Trioxide in Treating Patients With Urothelial Cancer |
| NCT00072150 | PHASE2 | COMPLETED | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
| NCT00661609 | PHASE2 | COMPLETED | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer |
| NCT00749892 | PHASE2 | COMPLETED | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer |
| NCT01191892 | PHASE2 | COMPLETED | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer |
| NCT01282463 | PHASE2 | COMPLETED | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma |
| NCT01326871 | PHASE1/PHASE2 | COMPLETED | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer |
| NCT01328574 | PHASE2 | COMPLETED | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma |
| NCT01426126 | PHASE2 | COMPLETED | Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum |
| NCT01639521 | PHASE2 | WITHDRAWN | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer |
| NCT02122172 | PHASE2 | TERMINATED | Afatinib in Advanced Refractory Urothelial Cancer |
| NCT02178241 | PHASE2 | COMPLETED | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery |
| NCT02665039 | PHASE2 | COMPLETED | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function |
| NCT03397394 | PHASE2 | TERMINATED | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
| NCT03513952 | PHASE2 | COMPLETED | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma |
| NCT03520231 | PHASE2 | COMPLETED | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases |
| NCT03617913 | PHASE2 | COMPLETED | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer |
| NCT04398368 | PHASE2 | TERMINATED | Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT04963153 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy |
| NCT01182168 | PHASE1 | COMPLETED | Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies |
| NCT01844947 | PHASE1 | COMPLETED | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract |
| NCT02300610 | PHASE1 | COMPLETED | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer |
| NCT03590054 | PHASE1 | COMPLETED | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies |
| NCT02812420 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery |
| NCT00902590 | Not specified | ACTIVE_NOT_RECRUITING | A Genotype-Phenotype Urothelial Cancer Registry |
| NCT02012699 | Not specified | RECRUITING | Integrated Cancer Repository for Cancer Research |
| NCT03291028 | Not specified | ACTIVE_NOT_RECRUITING | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma |
| NCT04197414 | Not specified | RECRUITING | Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA |
| NCT04625556 | Not specified | RECRUITING | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 6 |
| CABOZANTINIB | 4 | 4 |
| AFATINIB | 4 | 2 |
| ERIBULIN MESYLATE | 4 | 2 |
| VINFLUNINE | 4 | 2 |
| ARSENIC TRIOXIDE | 4 | 1 |
| AVELUMAB | 4 | 1 |
| FOLIC ACID | 4 | 1 |
| GEMCITABINE | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| PEMETREXED | 4 | 1 |
| RUCAPARIB | 4 | 1 |
| VANDETANIB | 4 | 1 |
| VINBLASTINE | 4 | 1 |
| CAROTUXIMAB | 3 | 1 |
| AZD-4877 | 2 | 1 |
| ICRUCUMAB | 2 | 1 |
| PEMVIDUTIDE | 2 | 1 |
| CHEMBL4788494 | 0 | 1 |